One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Editor's Choice – John Ingram – February 2024
doi : 10.1093/bjd/ljad496
Volume 190, Issue Supplement_2, February 2024
Is there a growing global threat of scabies treatment failure? An opportunity to discuss health inequity within UK dermatology
doi : 10.1093/bjd/ljad457
Omalizumab therapy of bullous pemphigoid
Janet A Fairley, Kelly A N Messingham
doi : 10.1093/bjd/ljad432
Changes in the epidemiology of atopic dermatitis: putting them into context
Joy Wan
doi : 10.1093/bjd/ljad443
Toward risk stratification and personalized therapy for neurofibromas in neurofibromatosis type 1
Carlos G Romo, Kavita Y Sarin, Jaishri O Blakeley
doi : 10.1093/bjd/ljad452
Decoding atopic dermatitis: unveiling phenotypes through data-driven methods
Simone Cazzaniga, Dagmar Simon
doi : 10.1093/bjd/ljad453
How to score the impact of treatment on cutaneous neurofibromas in clinical trials
Nicolas Ortonne
doi : 10.1093/bjd/ljad492
Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscapeÂ
James G Krueger, John Frew, Gregor B E Jemec, Alexa B Kimball, Brian Kirby, Falk G Bechara, Kristina Navrazhina, Errol Prens, Kristian Reich, Eva Cullen, Kerstin Wolk
doi : 10.1093/bjd/ljad345
Risk factors for subsequent primary melanoma in patients with previous melanoma: a systematic review and meta-analysis
doi : 10.1093/bjd/ljad275
Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis
doi : 10.1093/bjd/ljad393
Decreasing prevalence of atopic dermatitis in Swedish schoolchildren: three repeated population-based surveys
doi : 10.1093/bjd/ljad370
Assessing the genetic risk of nodular melanoma using a candidate gene approach
doi : 10.1093/bjd/ljad365
Atopic dermatitis phenotypes based on cluster analysis of the Danish Skin Cohort
doi : 10.1093/bjd/ljad401
A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials
doi : 10.1093/bjd/ljad397
Identification of potential common genetic modifiers of neurofibromas: a genome-wide association study in 1333 patients with neurofibromatosis type 1
doi : 10.1093/bjd/ljad390
A critical role of the endothelial S-phase kinase-associated protein 2/phosphatase and tensin homologue axis in angiogenesis and psoriasis
doi : 10.1093/bjd/ljad399
Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients
doi : 10.1093/bjd/ljad369
Harmonization of outcomes in epidermolysis bullosa: report of the Core Outcome Sets for Epidermolysis Bullosa (COSEB) kick-off meeting
doi : 10.1093/bjd/ljad361
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2023: a pragmatic update
doi : 10.1093/bjd/ljad347
Possible relation of cathepsin C activity and seasonal fluctuation of skin lesions in Papillon–Lefèvre syndrome
doi : 10.1093/bjd/ljad373
Top 10 research priorities for basal cell carcinoma: results of the Skin Investigation Network of Canada Priority Setting Initiative
doi : 10.1093/bjd/ljad391
Skin Investigation Network of Canada (SkINÂ Canada) Priority Setting Initiative ranks the top 10 evidence uncertainties for Merkel cell carcinoma
doi : 10.1093/bjd/ljad398
Disseminated juvenile xanthogranulomas with underlying neurotrophic tyrosine receptor kinase fusion and response to larotrectinib
doi : 10.1093/bjd/ljad427
Individuals with Darier disease have an increased risk of suicide and self-injurious behaviours
doi : 10.1093/bjd/ljad424
Janus kinase inhibitor for anti-transcription intermediary factor 1-γ positive cancer-associated dermatomyositis
doi : 10.1093/bjd/ljad396
Prevalence of chronic urticaria and healthcare usage of patients with the condition in primary care: a population-based study in the Netherlands
doi : 10.1093/bjd/ljad426
Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials
doi : 10.1093/bjd/ljad435
Elderly male patients with hidradenitis suppurativa have more severe disease independent of disease duration
doi : 10.1093/bjd/ljad411
Correction to: Treatment of moderate-to-severe alopecia areata in pre-adolescent children with baricitinib
doi : 10.1093/bjd/ljad368
Correction to: Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial
doi : 10.1093/bjd/ljad442
Hidradenitis suppurativa: a review with new insights into disease mechanisms and potential future treatments
doi : 10.1093/bjd/ljad512
Risk factors for developing a new primary melanoma in people with a melanoma
doi : 10.1093/bjd/ljad507
A study using machine learning to help identify subgroups of adults with atopic dermatitis
doi : 10.1093/bjd/ljad509
Outcomes that need to be assessed in clinical trials for cutaneous neurofibromas in people with neurofibromatosis type 1
doi : 10.1093/bjd/ljad515
A genetic study to understand more about the variability in appearance, number and growth of neurofibromas in people with neurofibromatosis type 1
doi : 10.1093/bjd/ljad508
Targeting Skp2 in blood vessels may be a promising approach to treat psoriasis
doi : 10.1093/bjd/ljad516
